Neuroblastoma (original) (raw)

• Goodman MT, Gumey JG, Smith MA, et al. Sympathetic nervous system tumors. In: Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. Bethesda (MD): National Cancer Institute SEER Program, 1999: 65–72
  Google Scholar
• Wright JH. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med 1910; 12: 556–61
  Article PubMed CAS Google Scholar
• Cushing H, Wolbach SB. The transformation of a malignant paravertebral sympathicoblastoma into benign ganglioneuroma. Am J Pathol 1927; 3: 203–16
  PubMed CAS Google Scholar
• Farber S, Toch R. Chemotherapy of disseminated neuroblastoma in children. Am J Dis Child 1951; 82: 239–41
  Google Scholar
• Pinkel D, Pratt C, Holton C, et al. Survival of children with neuroblastoma treated with combination chemotherapy. J Pediatr 1968; 73(6): 928–31
  Article PubMed CAS Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis retinoic acid: Children’s Cancer Group. N Engl J Med 1999; 341(16): 1165–73
  Article PubMed CAS Google Scholar
• Kushner BH, Gilbert F, Helson L. Familial neuroblastoma: case reports, literature review, and etiologic considerations. Cancer 1986; 57(9): 1887–93
  Article PubMed CAS Google Scholar
• Laureys G, Speleman F, Opdenakker G, et al. Constitutional translocation t(l; 17)(p36; ql2–21) in a patient with neuroblastoma. Genes Chromosomes Cancer 1990; 2(3): 252–4
  Article PubMed CAS Google Scholar
• Maris JM, Kyemba SM, Rebbeck TR, et al. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res 1996; 56(15): 3421–5
  PubMed CAS Google Scholar
• Biegel JA, White PS, Marshall HN, et al. Constitutional 1p36 deletion in a child with neuroblastoma. Am J Hum Genet 1993; 52(1): 176–82
  PubMed CAS Google Scholar
• Maris JM, Weiss MJ, Mosse Y, et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16pl2–13. Cancer Res 2002; 62(22): 6651–8
  PubMed CAS Google Scholar
• Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Reck-linghausen’s disease: a review of the literature. J Clin Oncol 1985; 3(1): 117–20
  PubMed CAS Google Scholar
• Maris JM, Chatten J, Meadows AT, et al. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol 1997; 28(1): 1–5
  Article PubMed CAS Google Scholar
• Kramer S, Ward E, Meadows AT, et al. Medical and drug risk factors associated with neuroblastoma: a case-control study. J Natl Cancer Inst 1987; 78(5): 797–804
  PubMed CAS Google Scholar
• Schwartzbaum JA. Influence of the mother’s prenatal drug consumption on risk of neuroblastoma in the child. Am J Epidemiol 1992; 135(12): 1358–67
  PubMed CAS Google Scholar
• Michalek AM, Buck GM, Nasca PC, et al. Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol 1996; 143(10): 996–1001
  Article PubMed CAS Google Scholar
• Kinney H, Faix R, Brazy J. The fetal alcohol syndrome and neuroblastoma. Pediatrics 1980; 66(1): 130–2
  PubMed CAS Google Scholar
• Olshan AF, Smith J, Cook MN, et al. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. Am J Epidemiol 1999; 150(9): 930–8
  Article PubMed CAS Google Scholar
• Daniels JL, Olshan AF, Pollock BH, et al. Breast-feeding and neuroblastoma, USA and Canada. Cancer Causes Control 2002; 13(5): 401–5
  Article PubMed Google Scholar
• Buck GM, Michalek AM, Chen CJ, et al. Perinatal factors and risk of neuroblastoma. Paediatr Perinat Epidemiol 2001; 15(1): 47–53
  Article PubMed CAS Google Scholar
• Olshan AF, De Roos AJ, Teschke K, et al. Neuroblastoma and parental occupation. Cancer Causes Control 1999; 10(6): 539–49
  Article PubMed CAS Google Scholar
• Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 1995; 13(8): 2033–8
  PubMed CAS Google Scholar
• Asami T, Otabe N, Wakabayashi M, et al. Screening for neuroblastoma: a 9-year birth cohort-based study in Niigata, Japan. Acta Paediatr 1995; 84(10): 1173–6
  Article PubMed CAS Google Scholar
• Hanawa Y, Sawada T, Tsunoda A. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 1990; 18(6): 472–5
  Article PubMed CAS Google Scholar
• Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348(9043): 1682–7
  Article PubMed CAS Google Scholar
• Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002; 346(14): 1041–6
  Article PubMed Google Scholar
• Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002; 346(14): 1047–53
  Article PubMed Google Scholar
• Quak SH, Prabhakaran K, Kwok R, et al. Vasoactive intestinal peptide secreting tumours in children: a case report with literature review. Aust Paediatr J 1988; 24(1): 55–8
  PubMed CAS Google Scholar
• Qualman SJ, O’Dorisio MS, Fleshman DJ, et al. Neuroblastoma: correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer 1992; 70(7): 2005–12
  Article PubMed CAS Google Scholar
• Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22(4): 315–20
  Article PubMed CAS Google Scholar
• Russo C, Cohn SL, Petruzzi MJ, et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28(4): 284–8
  Article PubMed CAS Google Scholar
• Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies: a report from the Children’s Cancer Group study. Med Pediatr Oncol 2001; 36(6): 612–22
  Article PubMed CAS Google Scholar
• Boltshauser E, Deonna T, Hirt HR. Myoclonic encephalopathy of infants or ‘dancing eyes syndrome’: report of 7 cases with long-term follow-up and review of the literature (cases with and without neuroblastoma). Helv Paediatr Acta 1979; 34(2): 119–33
  PubMed CAS Google Scholar
• Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109(1): 86–98
  PubMed Google Scholar
• Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001; 139(4): 552–9
  Article PubMed CAS Google Scholar
• Koh PS, Raffensperger JG, Berry S, et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994; 125 (5 Pt 1): 712–6
  Article PubMed CAS Google Scholar
• Numata K, Kusui H, Kawakatsu H, et al. Increased urinary HVA levels in neuroblastoma screens related to diet, not tumor. Pediatr Hematol Oncol 1997; 14(6): 569–76
  Article PubMed CAS Google Scholar
• Lau L. Neuroblastoma: a single institution’s experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 2002; 19(2): 79–89
  Article PubMed Google Scholar
• Garaventa A, Boni L, Lo Piccolo MS, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 2002; 13(6): 956–64
  Article PubMed CAS Google Scholar
• Connolly LP, Drubach LA, Ted Treves S. Applications of nuclear medicine in pediatric oncology. Clin Nucl Med 2002; 27(2): 117–25
  Article PubMed Google Scholar
• Shulkin BL, Wieland DM, Baro ME, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996; 37(1): 16–21
  PubMed CAS Google Scholar
• Kushner BH, Yeung HW, Larson SM, et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19(14): 3397–405
  PubMed CAS Google Scholar
• Brodeur AE, Brodeur GM. Abdominal masses in children: neuroblastoma, Wilms tumor, and other considerations. Pediatr Rev 1991; 12(7): 196–207
  Article PubMed CAS Google Scholar
• Sauvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 2002; 94(9): 2474–80
  Article PubMed Google Scholar
• Ho PT, Estroff JA, Kozakewich H, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children’s Hospital. Pediatrics 1993; 92(3): 358–64
  PubMed CAS Google Scholar
• Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11(8): 1466–77
  PubMed CAS Google Scholar
• Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children’s Cancer Group study. J Clin Oncol 2000; 18(1): 18–26
  PubMed CAS Google Scholar
• Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 1998; 16(4): 1256–64
  PubMed CAS Google Scholar
• Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children’s Cancer Group study. J Clin Oncol 2000; 18(6): 1260–8
  PubMed CAS Google Scholar
• Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 2000; 18(3): 477–86
  PubMed CAS Google Scholar
• Shimada H, Chatten J, Newton Jr WA, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73(2): 405–16
  PubMed CAS Google Scholar
• Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86(2): 364–72
  Article PubMed CAS Google Scholar
• Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313(18): 1111–6
  Article PubMed CAS Google Scholar
• Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334(4): 225–30
  Article PubMed CAS Google Scholar
• Nakagawara A, Arima Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847–54
  Article PubMed CAS Google Scholar
• Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9(4): 581–91
  PubMed CAS Google Scholar
• Kohl NE, Gee CE, Alt FW. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 1984; 226(4680): 1335–7
  Article PubMed CAS Google Scholar
• Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121–4
  Article PubMed CAS Google Scholar
• Weiss WA, Aldape K, Mohapatra G, et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16(11): 2985–95
  Article PubMed CAS Google Scholar
• Chan HS, Gallie BL, DeBoer G, et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997; 3(10): 1699–706
  PubMed CAS Google Scholar
• Brodeur GM, Maris JM, Yamashiro DJ, et al. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997; 19(2): 93–101
  Article PubMed CAS Google Scholar
• Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol 1997; 15(1): 85–93
  PubMed CAS Google Scholar
• Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience. A Pediatric Oncology Group study. J Clin Oncol 1998; 16(6): 2007–17
  PubMed CAS Google Scholar
• George RE, Variend S, Cullinane C, et al. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. Med Pediatr Oncol 2001; 36(1): 169–76
  Article PubMed CAS Google Scholar
• Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995; 87(19): 1470–6
  Article PubMed CAS Google Scholar
• Gilbert F, Balaban G, Moorhead P, et al. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet 1982; 7(1): 33–42
  Article PubMed CAS Google Scholar
• White PS, Maris JM, Beltinger C, et al. A region of consistent deletion in neuroblastoma maps within human chromosome lp36.2-36.3. Proc Natl Acad Sci U S A 1995; 92(12): 5520–4
  Article PubMed CAS Google Scholar
• Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995; 55(20): 4664–9
  PubMed CAS Google Scholar
• Gehring M, Berthold F, Edler L, et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995; 55(22): 5366–9
  PubMed CAS Google Scholar
• Martinsson T, Sjoberg RM, Hedborg F, et al. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 1995; 55(23): 5681–6
  PubMed CAS Google Scholar
• Maris JM, Guo C, White PS, et al. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol 2001; 36(1): 24–7
  Article PubMed CAS Google Scholar
• Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999; 18(35): 4948–57
  Article PubMed CAS Google Scholar
• Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340(25): 1954–61
  Article PubMed CAS Google Scholar
• Bown N, Lastowska M, Cotterill S, et al. 17q gain in neuroblastoma predicts adverse clinical outcome: UK Cancer Cytogenetics Group and the UK Children’s Cancer Study Group. Med Pediatr Oncol 2001; 36(1): 14–9
  Article PubMed CAS Google Scholar
• Lastowska M, Cotterill S, Bown N, et al. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 2002; 34(4): 428–36
  Article PubMed CAS Google Scholar
• Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984; 311: 231–5
  Article PubMed CAS Google Scholar
• Gansler T, Chatten J, Varello M, et al. Flow cytometric DNA analysis of neuroblastoma: correlation with histology and clinical outcome. Cancer 1986; 58: 2453–8
  Article PubMed CAS Google Scholar
• Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997; 89(5): 373–80
  Article PubMed CAS Google Scholar
• Tanaka T, Seeger RC, Tanabe M, et al. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification. Cancer Detect Prev 1994; 18(4): 283–9
  PubMed CAS Google Scholar
• Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85: 377–84
  Article PubMed CAS Google Scholar
• Yamashiro DJ, Nakagawara A, Ikegaki N, et al. Expression of TrkC in favorable human neuroblastomas. Oncogene 1996; 12(1): 37–41
  PubMed CAS Google Scholar
• Ryden M, Sehgal R, Dominici C, et al. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 1996; 74(5): 773–9
  Article PubMed CAS Google Scholar
• Azar CG, Scavarda NJ, Nakagawara A, et al. Expression and function of the nerve growth factor receptor (TRK-A) in human neuroblastoma cell lines. Prog Clin Biol Res 1994; 385: 169–75
  PubMed CAS Google Scholar
• Tanaka T, Hiyama E, Sugimoto T, et al. trk A gene expression in neuroblastoma: the clinical significance of an immunohistochemical study. Cancer 1995; 76(6): 1086–95
  Article PubMed CAS Google Scholar
• Nakagawara A, Azar CG, Scavarda NJ, et al. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14(1): 759–67
  PubMed CAS Google Scholar
• Streutker CJ, Thorner P, Fabricius N, et al. Telomerase activity as a prognostic factor in neuroblastomas. Pediatr Dev Pathol 2001; 4(1): 62–7
  Article PubMed CAS Google Scholar
• Hiyama E, Hiyama K, Yokoyama T, et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995; 1(3): 249–55
  Article PubMed CAS Google Scholar
• Nitschke R, Smith El, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group study. J Clin Oncol 1988; 6(8): 1271–9
  PubMed CAS Google Scholar
• Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998; 16(4): 1265–9
  PubMed CAS Google Scholar
• Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 1997; 33(12): 2121–5
  Article PubMed CAS Google Scholar
• Plantaz D, Rubie H, Michon J, et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease: a prospective study of 42 patients. Results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer 1996; 78(2): 311–9
  Article PubMed CAS Google Scholar
• De Bernardi B, Pianca C, Boni L, et al. Disseminated neuroblastoma (stage IV and IV-S) in the first year of life: outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer 1992; 70(6): 1625–33
  Article PubMed Google Scholar
• Nickerson HJ, Nesbit ME, Grosfeld JL, et al. Comparison of stage IV and IV-S neuroblastoma in the first year of life. Med Pediatr Oncol 1985; 13: 261–8
  Article PubMed CAS Google Scholar
• Strother D, Shuster JJ, McWilliams N, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 1995; 17(3): 254–9
  Article PubMed CAS Google Scholar
• Roberts S, Creamer K, Shoupe B, et al. Unique management of stage 4S neuroblastoma complicated by massive hepatomegaly: case report and review of the literature. J Pediatr Hematol Oncol 2002; 24(2): 142–4
  Article PubMed Google Scholar
• McGahren ED, Rodgers BM, Waldron PE. Successful management of stage 4S neuroblastoma and severe hepatomegaly using absorbable mesh in an infant. J Pediatr Surg 1998; 33(10): 1554–7
  Article PubMed CAS Google Scholar
• Matthay KK. Neuroblastoma: biology and therapy. Oncology 1997; 11(12): 1857–66
  PubMed CAS Google Scholar
• Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994; 12(12): 2607–13
  PubMed CAS Google Scholar
• Pinkerton CR. ENSG 1-randomised study of high-dose melphalan in neuroblastoma. Bone Marrow Transplant 1991; 7Suppl. 3: 112–3
  PubMed Google Scholar
• Ladenstein R, Lasset C, Hartmann O, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14(1): 37–46
  PubMed CAS Google Scholar
• Matthay KK, O’Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children’s Cancer Group results. Eur J Cancer 1995; 31A(4): 572–5
  Article PubMed CAS Google Scholar
• Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children’s Cancer Group. J Clin Oncol 1994; 12(11): 2382–9
  PubMed CAS Google Scholar
• Reynolds CP, Seeger RC, Vo DD, et al. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46(11): 5882–6
  PubMed CAS Google Scholar
• Handgretinger R, Lang P, Ihm K, et al. Isolation and transplantation of highly purified autologous peripheral CD34 (+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 2002; 29(9): 731–6
  Article PubMed CAS Google Scholar
• Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000; 18(13): 2567–75
  PubMed CAS Google Scholar
• Tchirkov A, Kanold J, Giollant M, et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 1998; 30(4): 228–32
  Article PubMed CAS Google Scholar
• Moss TJ, Reynolds CP, Sather HN, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991; 324: 219–26
  Article PubMed CAS Google Scholar
• Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001; 19(6): 1795–801
  PubMed CAS Google Scholar
• Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children’s Cancer Group study. J Clin Oncol 2000; 18(24): 4067–76
  PubMed CAS Google Scholar
• Cheung IY, Lo Piccolo MS, Kushner BH, et al. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003; 21(6): 1087–93
  Article PubMed CAS Google Scholar
• Donovan J, Temel J, Zuckerman A, et al. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol 2000; 35(6): 677–82
  Article PubMed CAS Google Scholar
• Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997; 33(12): 2130–5
  Article PubMed CAS Google Scholar
• Villablanca JG, Matthay KK, Swift PS, et al. Phase I trial of carboplatin, etoposide, melphalan and local irradiation (CEM-LI) with purged autologous bone marrow transplantation for children with high risk neuroblastoma [abstract]. Med Pediatr Oncol 1999; 33: 170
  Google Scholar
• Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993; 67(1): 119–27
  Article PubMed CAS Google Scholar
• Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II study. J Clin Oncol 2002; 20(9): 2284–92
  Article PubMed CAS Google Scholar
• Shorter NA, Davidoff AM, Evans AE, et al. The role of surgery in the management of stage IV neuroblastoma: a single institution study. Med Pediatr Oncol 1995; 24(5): 287–91
  Article PubMed CAS Google Scholar
• La Quaglia MP, Kushner BH, Heller G, et al. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 1994; 29(8): 1162–5
  Article PubMed Google Scholar
• Haase GM, O’Leary MC, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 1991; 26(9): 1119–23
  Article PubMed CAS Google Scholar
• Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 1999; 3Suppl. 1: 72–7
  Article PubMed Google Scholar
• Wolden SL, Gollamudi SV, Kushner BH, et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys 2000; 46(4): 969–74
  Article PubMed CAS Google Scholar
• Haase GM, Meagher Jr DP, McNeely LK, et al. Electron beam intraoperative radiation therapy for pediatric neoplasms. Cancer 1994; 74(2): 740–7
  Article PubMed CAS Google Scholar
• Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study. Int J Radiat Oncol Biol Phys 2003; 56(1): 28–39
  Article PubMed Google Scholar
• Paulino AC, Mayr NA, Simon JH, et al. Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys 2002; 52(4): 1025–31
  Article PubMed Google Scholar
• Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001; 15(5): 867–910
  Article PubMed CAS Google Scholar
• Abemayor E, Chang B, Sidell N. Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett 1990; 55(1): 1–5
  Article PubMed CAS Google Scholar
• Kohler JA, Imeson J, Ellershaw C, et al. A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 2000; 83(9): 1124–7
  Article PubMed CAS Google Scholar
• Maurer BJ, Metelitsa LS, Seeger RC, et al. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblas-toma cell lines. J Nati Cancer Inst 1999; 91(13): 1138–46
  Article CAS Google Scholar
• Munkner T. 1311-meta-iodobenzylguanidine scintigraphy of neuroblastomas. Semin Nucl Med 1985; 15(2): 154–60
  Article PubMed CAS Google Scholar
• Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229–36
  PubMed CAS Google Scholar
• Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. J Clin Oncol 1992; 10(12): 1889–96
  PubMed CAS Google Scholar
• Troncone L, Rufini V, Luzi S, et al. The treatment of neuroblastoma with [131I]MIBG at diagnosis. Q J Nucl Med 1995; 39 (4 Suppl. 1): 65–8
  PubMed CAS Google Scholar
• Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84(4): 460–4
  Article PubMed CAS Google Scholar
• Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20(8): 2142–9
  Article PubMed CAS Google Scholar
• Anderson CP, Tsai JM, Chan WW, et al. Buthionine sulfoximine (BSO) is cytotoxic and enhances the activity of melphalan for human neuroblastoma cell lines. Eur J Cancer 1997; 33: 2016–9
  Article PubMed CAS Google Scholar
• Bailey H. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994; 12(1): 194–205
  PubMed CAS Google Scholar
• Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G (D2) monoclonal antibody (ch 14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group study. J Clin Oncol 2000; 18(24): 4077–85
  PubMed CAS Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch 14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998; 16(6): 2169–80
  PubMed CAS Google Scholar
• Cheung NK, Kushner BH, Cheung IY, et al. Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16(9): 3053–60
  PubMed CAS Google Scholar
• Hank JA, Surfus J, Gan J, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994; 15(1): 29–37
  Article CAS Google Scholar
• Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children’s Cancer Group. Cancer 1997; 80(2): 317–33
  Article PubMed CAS Google Scholar
• Lode HN, Xiang R, Duncan SR, et al. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A 1999; 96(15): 8591–6
  Article PubMed CAS Google Scholar
• Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998; 92(6): 1941–9
  PubMed CAS Google Scholar
• Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998; 9(9): 1303–11
  Article PubMed CAS Google Scholar